Dr Ananda Amarasinghe explains that booster doses sustain the immune protection against COVID-19 and should be prioritized for those at highest risk of serious COVID-19 illness Créditos: Comité científico Covid
Read More
Booster doses of COVID-19 vaccines were recommended for people aged 18 years or older in November 2021 following the recommendation of an additional primary dose of COVID-19 vaccine for select immunocompromised populations on August 13, 2021.1 As of February 26, 2022, more than 93 million booster doses of COVID-19 vaccines had […]
Read More
The COVID-19 mRNA vaccines’ 2-dose primary series appeared to provide less protection against hospitalization from Omicron variant infections than Alpha and Delta infections, according to a recent study. A booster dose, however, was associated with increased effectiveness against Omicron hospitalizations at the same high levels achieved against earlier variants with 2 […]
Read More
The Centers for Medicare & Medicaid Services (CMS) now provides data on COVID-19 vaccine booster shots among residents and staff at nursing homes. The data, which feature both completed vaccination and booster rates for individual facilities, is accessible via the Medicare.gov Care Compare website. State and national averages of completed vaccination […]
Read More
The FDA today announced its vaccines advisory committee will meet April 6 to discuss the future of COVID-19 booster doses and how to tell if a specific strain of the coronavirus needs its own vaccine. The independent experts on the Vaccines and Related Biological Products Advisory Committee will be joined by representatives […]
Read More
Créditos: Comité científico Covid
Read More
Summary What is already known about this topic? Adults aged ≥18 years reported adverse reactions less frequently after receipt of a homologous Pfizer-BioNTech COVID-19 booster dose than after the second primary dose. What is added by this report? Among persons aged 12–17 years, reactions after Pfizer-BioNTech booster vaccination were generally […]
Read More
Moderna Inc executives said on Thursday they believe a fourth COVID-19 vaccine shot will be needed late this year due to waning protection from earlier doses, which could push up sales in the second half of 2022. Chief Executive Stephane Bancel stressed that the company’s current sales projections for its […]
Read More
Protection against COVID-19 waned 4 to 5 months after a third dose of Pfizer (Comirnaty) or Moderna’s (Spikevax) vaccine, with steeply declining protection against emergency department (ED) visits as well as hospitalization during Omicron, researchers found. During the Omicron period, vaccine effectiveness (VE) against ED or urgent care visits was […]
Read More
A recent study shows that two doses of mRNA (Pfizer-BioNTech or Moderna) or one dose of viral vector (Johnson & Johnson) COVID-19 vaccines were insufficient to produce adequate immunity to a lab-created Omicron variant or pseudovirus. The Omicron pseudovirus infected cells at a higher rate than other pseudovirus variants. The […]
Read More